Categories: Health

Intas Pharmaceuticals Launches HETRONIFLY (Serplulimab), India’s First Novel Immunotherapy for Advanced Small Cell Lung Cancer

AHMEDABAD, India, Aug. 5, 2025 /PRNewswire/ — Intas Pharmaceuticals has launched HETRONIFLY™ (Serplulimab), the first PD-1 inhibitor globally approved for the treatment of Extensive-Stage Small Cell Lung Cancer (ES-SCLC), in the Indian market. This marks another major milestone, following the successful Launch in Europe.

- Advertisement -

This launch follows a strategic licensing agreement between Intas Pharmaceuticals Limited and Shanghai Henlius Biotech, Inc., further strengthening Intas’ oncology portfolio and reinforcing its commitment to delivering cutting-edge therapies to patients in India.

- Advertisement -

Serplulimab is the first PD-1 inhibitor worldwide to receive approval for ES-SCLC, and is currently present in over 40 countries, including key European markets. Its efficacy is supported by the landmark ASTRUM-005 trial, which demonstrated a 40% reduction in the risk of death and remarkably higher overall survival rate versus the current standard-of-care Chemotherapy regimen. Notably, Serplulimab achieved an ESMO-MCBS score of 4/5—the highest among current immunotherapies, signifying highest clinical benefit in this indication.

- Advertisement -

The novel humanized mAb has a unique dual-blockade mechanism of PD-L1 and PD-L2, along with the highest PD-1 internalization, which sets a new benchmark in deep immune engagement for solid tumors. Globally, Serplulimab has been administered to over a lakh patients across a range of malignancies including SCLC, NSCLC, ESCC, and MSI-high cancers.

- Advertisement -

Despite the promise of immuno-oncology, cost remains a significant barrier in India. HETRONIFLY™, introduced at approximately 75% lower cost than the currently available immunotherapies for this indication, underscores Intas’ commitment to providing high-quality innovative therapies at affordable prices to cancer patients in India.

- Advertisement -

Commenting on the launch, Binish Chudgar, Chairman & Managing Director of Intas Pharmaceuticals said, “The launch of HETRONIFLY™ reinforces our strategic position in oncology and reflects Intas’ commitment to accelerating access to globally validated therapies. It aligns with our operating model of delivering high-impact innovations to the Indian market with speed and cost-efficiency.”

- Advertisement -

Logo: https://mma.prnewswire.com/media/2514170/4930499/Intas_Accord_Logo.jpg

- Advertisement -

 

- Advertisement -

View original content:https://www.prnewswire.com/in/news-releases/intas-pharmaceuticals-launches-hetronifly-serplulimab-indias-first-novel-immunotherapy-for-advanced-small-cell-lung-cancer-302522015.html

- Advertisement -
PRNW Agency

Recent Posts

Mochi Drops the ‘Lit Collection’ – Crackling Festive Footwear for this Diwali 2025

MUMBAI, India, Oct. 7, 2025 /PRNewswire/ -- Mochi, India's go-to destination for stylish footwear, is…

1 hour ago

Ingka Group acquires Locus, an AI-powered logistics software company to transform the IKEA home delivery experience

MALMÖ, Sweden, Oct. 7, 2025 /PRNewswire/ -- Ingka Investments, the investment arm of Ingka Group,…

1 hour ago

NOBU HOSPITALITY ANNOUNCES NOBU HOTEL AND RESTAURANT NASHVILLE

Bringing Nobu's Signature Lifestyle and World-Renowned Cuisine to the Music City NEW YORK, Oct. 8,…

1 hour ago

Department of Culture and Tourism – Experience Abu Dhabi: Celebrities Spotted at NBA Abu Dhabi Games 2025

From Hollywood A-lister Adrien Brody to Bollywood superstar Ranveer Singh, here are all the celebrities…

1 hour ago

TEADIT OPENS NEW FACILITY IN INDIA

Annual Distributor Event Held at New Facility VADODARA, India, Oct. 8, 2025 /PRNewswire/ -- Teadit® is…

3 hours ago

Relativity Fest 2025: Relativity Announces Generative AI Solutions for Legal Review to Be Standard in Cloud Offering

News Summary: Generative AI solutions for review, such as Relativity aiR for Review and Relativity…

3 hours ago